InflaRx N.V. (IFRX) research

InflaRx N.V.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$2.08
As of

InflaRx N.V. (IFRX): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-08-06.

As of . Source: SEC EDGAR filings for IFRX. Method and limitations.

SHARE THIS CARD

Share the IFRX intelligence card

A branded snapshot of IFRX: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion IFRX intelligence card preview
Post to X
LIVE TERMINAL

See IFRX live in the terminal

Track IFRX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live IFRX terminal, free

Active signals for IFRX

FREE, NO ACCOUNT

Every signal on IFRX, as it fires

You are seeing 5 of 17 signals recorded on IFRX since 2026-05-17.

The five above landed across 2 days. The other 12 were recorded on 5 other days. 11 of the 17 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in IFRX (2026Q2)

Manager / securityMarket value% portfolioQoQ
MILLENNIUM MANAGEMENT LLCCUSIP N44821101 · 2026Q2$1.3M0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP N44821101 · 2026Q2$406K0.00%,
CITADEL ADVISORS LLCCUSIP N44821101 · 2026Q2$312K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, IFRX

IFRX against its peers

IFRX's net margin of -155582.1% ranks in the 4th percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-05-31.

MetricIFRXPeer medianPercentilen
Revenue FY29331 EURn/an/a0
Revenue YoY-82.3%n/an/a0
Gross margin-24677.9%n/an/a1
Operating marginn/a-154.5%n/a13
Net margin-155582.1%-125.4%413
Return on equity-109.8%-33.5%1121

Peers (23): QTTB, VNDA, IKT, ABEO, SABS, FATE, SION, ZNTL, EYPT, STRO, UPB, IPSC, IMRX, CYDY, CMPX, LXEO, EVMN, EBS, GLSI, PALI, ANIK, ENTA, XFOR. Left out: VCRE (no annual filing), CUVL (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (IFRX: 20-F), reported in EUR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more IFRX signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to IFRXand get the insider, 13F, options, and confluence read in one view.

Open the live IFRX terminal, free